Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023-Reference-Cited by-同舟云学术

Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023

Published:2024-01-04 Issue:1 Volume:29 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Fontán-Vela Mario¹²^ORCID,Kissling Esther³,Nicolay Nathalie⁴,Braeye Toon⁵,Van Evercooren Izaak⁵,Holm Hansen Christian⁶,Emborg Hanne-Dorthe⁶,Fabiani Massimo⁷,Mateo-Urdiales Alberto⁷,AlKerwi Ala'a⁸,Schmitz Susanne⁸,Castilla Jesús⁹¹⁰,Martínez-Baz Iván⁹¹⁰,de Gier Brechje¹¹,Hahné Susan¹¹,Meijerink Hinta¹²,Starrfelt Jostein¹²,Nunes Baltazar¹³,Caetano Constantino¹³,Derrough Tarik⁴,Nardone Anthony³,Monge Susana¹⁴²,

Affiliation:

1. Public Health and Epidemiology research group, School of Medicine and Health Sciences, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain

2. National Centre of Epidemiology, Carlos III National Health Institute (ISCIII), Madrid, Spain

3. Epiconcept, Paris, France

4. Vaccine Preventable Diseases and Immunisation, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

5. Sciensano, Elsene, Belgium

6. Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut (SSI), Copenhagen, Denmark

7. Infectious Diseases Department, Istituto Superiore di Sanità, Rome, Italy

8. Ministry of Health, Directorate of Health, Service epidemiology and statistics, Luxembourg

9. CIBER Epidemiología y Salud Pública (CIBERESP), Spain

10. Instituto de Salud Pública de Navarra – IdiSNA, Pamplona, Spain

11. Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands

12. Norwegian Institute of Public Health (NIPH), Oslo, Norway

13. Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Departamento de Epidemiologia, Lisboa, Portugal

14. CIBER on Infectious Diseases (CIBERINFEC), Madrid, Spain

Abstract

To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Reference18 articles.

1. Epiconcept. Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza. Paris: Epiconcept. [Accessed 6 Oct 2023]. Available from: https://www.epiconcept.fr/en/epidemio-project/vaccine-effectiveness-burden-and-impact-studies-vebis-of-covid-19-and-influenza

2. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.;Sentís;Euro Surveill,2022

3. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in ≥65 years old population in six European countries, October 2021 to November 2022.;Kislaya;Influenza Other Respir Viruses,2023

4. European Centre for Disease Prevention and Control (ECDC). Interim analysis of COVID-19 vaccine effectiveness against hospitalisation and death using electronic health records in six European countries. Stockholm: ECDC; 30 Nov 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/interim-analysis-covid-19-vaccine-effectiveness-against-hospitalisation-and-death

5. European Centre for Disease Prevention and Control (ECDC). Pilot protocol for a COVID-19 vaccine effectiveness study using health data registries: version 1.0. Stockholm: ECDC; 19 Sep 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-pilot-protocol-vaccine-effectiveness-study-using-health-data-registries

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study;Influenza and Other Respiratory Viruses;2024-04